These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23092025)

  • 21. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis.
    Van Bortel LM; Fici F; Mascagni F
    Am J Cardiovasc Drugs; 2008; 8(1):35-44. PubMed ID: 18303936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men.
    Brixius K; Middeke M; Lichtenthal A; Jahn E; Schwinger RH
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):327-31. PubMed ID: 17324145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS).
    Czuriga I; Riecansky I; Bodnar J; Fulop T; Kruzsicz V; Kristof E; Edes I; ;
    Cardiovasc Drugs Ther; 2003 May; 17(3):257-63. PubMed ID: 14574084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative assessment of antihypertensive efficacy of DL-nebivolol and D-nebivolol in patients with confirmed mild to moderate hypertension.
    Lacourcière Y; Poirier L; Lefebvre J; Archambault F; Cléroux J
    J Cardiovasc Pharmacol; 1995 Apr; 25(4):619-24. PubMed ID: 7596131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nebivolol monotherapy in younger adults (younger than 55 years) with hypertension: a randomized, placebo-controlled trial.
    Giles TD; Khan BV; Lato J; Brener L; Ma Y; Lukic T
    J Clin Hypertens (Greenwich); 2013 Sep; 15(9):687-93. PubMed ID: 24034663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Left ventricular mass and mechanics in mild-to-moderate hypertension: effect of nebivolol versus telmisartan.
    Fountoulaki K; Dimopoulos V; Giannakoulis J; Zintzaras E; Triposkiadis F
    Am J Hypertens; 2005 Feb; 18(2 Pt 1):171-7. PubMed ID: 15752943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study.
    Tzemos N; Lim PO; MacDonald TM
    Circulation; 2001 Jul; 104(5):511-4. PubMed ID: 11479245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial.
    Van Nueten L; Lacourcière Y; Vyssoulis G; Korlipara K; Marcadet DM; Dupont AG; Robertson JI
    Am J Ther; 1998 Jul; 5(4):237-43. PubMed ID: 10099065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of antihypertensive and beta 1-adrenoceptor antagonist effect of nebivolol and atenolol in essential hypertension.
    Simon G; Johnson ML
    Clin Exp Hypertens; 1993 May; 15(3):501-9. PubMed ID: 8098243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nebivolol efficacy and safety in patients with stage I-II hypertension.
    Greathouse M
    Clin Cardiol; 2010 Apr; 33(4):E20-7. PubMed ID: 20162736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study.
    Briasoulis A; Oliva R; Kalaitzidis R; Flynn C; Lazich I; Schlaffer C; Bakris G
    J Clin Hypertens (Greenwich); 2013 Jul; 15(7):473-9. PubMed ID: 23815535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of nebivolol and atenolol on central aortic pressure in hypertensive patients: a multicenter, randomized, double-blind study.
    Redón J; Pascual-Izuel JM; Rodilla E; Vicente A; Oliván J; Bonet J; Torguet JP; Calaforra O; Almirall J
    Blood Press; 2014 Jun; 23(3):181-8. PubMed ID: 24059690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and tolerability of nebivolol in stage I-II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials.
    Weiss RJ; Saunders E; Greathouse M
    Clin Ther; 2011 Sep; 33(9):1150-61. PubMed ID: 21864908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Heart rate variability dynamics during treatment of arterial hypertension].
    Riabykina GV; Chazova IE; Mychka VB; Shutova LI; Shishova TV; Liutikova LN; Kozhemiakina ESh; Shchedrina EV; Sobolev AV
    Kardiologiia; 2008; 48(7):18-24. PubMed ID: 18789021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Use of nebivolol in patients with mild and moderate hypertension].
    Zhigunova LV; Lakhova EL; Iurenev AP
    Ter Arkh; 2003; 75(3):59-61. PubMed ID: 12718224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of nebivolol on fibrinolytic parameters in mild and moderate hypertensive patients.
    Tarighi B; Kurum T; Demir M; Azcan SN
    Can J Cardiol; 2007 Jun; 23(8):651-5. PubMed ID: 17593991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nebivolol withdrawal results in blood pressure returning toward pretreatment levels, but without rebound symptoms: phase IV randomized trial.
    Lewin A; Lasseter KC; Dong F; Whalen JC
    J Am Soc Hypertens; 2012; 6(3):228-36. PubMed ID: 22421631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness.
    Kampus P; Serg M; Kals J; Zagura M; Muda P; Karu K; Zilmer M; Eha J
    Hypertension; 2011 Jun; 57(6):1122-8. PubMed ID: 21536983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vascular effects of nebivolol added to hydrochlorothiazide in African Americans with hypertension and echocardiographic evidence of diastolic dysfunction: the NASAA study.
    Khan BV; Rahman ST; Haque T; Merchant N; Bhaheetharan S; Harris J; Umar K; Wahi J; Ferdinand KC
    J Cardiovasc Pharmacol Ther; 2012 Sep; 17(3):291-7. PubMed ID: 22388001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.